Grufity logoGrufity logo

Integra LifeSciences Holdings Corp Stock Research

IART

53.09USD-1.00(-1.85%)Market Closed

Market Summary

USD53.09-1.00
Market Closed
-1.85%

IART Alerts

IART Stock Price

IART RSI Chart

IART Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

24.42

Price/Sales (Trailing)

2.83

EV/EBITDA

18.07

Price/Free Cashflow

19.85

IART Price/Sales (Trailing)

IART Profitability

EBT Margin

13.73%

Return on Equity

10.01%

Return on Assets

4.64%

Free Cashflow Yield

5.04%

IART Fundamentals

IART Revenue

Revenue (TTM)

1.6B

Revenue Y/Y

-1.85%

Revenue Q/Q

3.33%

IART Earnings

Earnings (TTM)

180.6M

Earnings Y/Y

16.66%

Earnings Q/Q

6.07%

Price Action

52 Week Range

40.6767.14
(Low)(High)

Last 7 days

-1.5%

Last 30 days

-9.0%

Last 90 days

-5.8%

Trailing 12 Months

-18.2%

IART Financial Health

Current Ratio

3.62

Debt/Equity

0.45

Debt/Cashflow

0.33

IART Investor Care

Buy Backs (1Y)

2.02%

Diluted EPS (TTM)

2.16

Peers (Alternatives to Integra LifeSciences Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
176.3B
31.5B
-6.84% -10.46%
24.46
5.6
6.85% 12.06%
104.3B
30.8B
-7.09% -24.59%
25.66
3.39
-3.19% -17.38%
103.3B
18.4B
2.26% 8.00%
43.81
5.6
7.84% 18.25%
82.0B
6.2B
-4.47% -13.27%
61.99
13.17
8.97% -22.43%
48.3B
5.4B
2.41% -25.12%
31.77
8.98
2.86% 1.25%
MID-CAP
9.8B
847.1M
-3.64% 34.52%
-4.9K
11.56
13.32% -137.89%
5.2B
1.0B
-11.64% -20.31%
30.37
5.12
6.76% 24.45%
4.4B
1.6B
-8.98% -18.20%
24.42
2.83
0.99% 6.79%
3.3B
410.9M
4.51% -3.13%
-28.67
8.11
27.29% -14.60%
3.0B
284.4M
-11.77% 2.91%
76.18
10.38
23.40% 58.18%
SMALL-CAP
917.3M
154.8M
-6.04% 0.61%
-8.82
5.93
60.29% -2309.58%
896.3M
222.4M
-8.27% -33.23%
-611.78
4.03
36.07% -119.34%
52.5M
13.1M
-11.48% -68.24%
-0.74
4
13.64% 4.49%
8.9M
3.5M
-28.10% -68.62%
-0.66
2.5
44.21% -50.10%

Financials for Integra LifeSciences Holdings

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-0.5%1,5581,5651,5671,5591,542
  S&GA Expenses-1.6%616627639641637
Costs and Expenses-1.3%1,3191,3361,3461,3461,345
EBITDA5.3%263250242236-
EBITDA Margin5.8%0.17*0.16*0.15*0.15*-
Earnings Before Taxes6.2%214201193187215
EBT Margin6.7%0.14*0.13*0.12*0.12*-
Interest Expenses1.6%50.0049.0048.0049.0050.00
Net Income4.4%181173166157169
Net Income Margin4.9%0.12*0.11*0.11*0.10*-
Free Cahsflow15.0%222193209237-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets2.2%3,8903,8073,7533,6723,782
  Current Assets-2.9%1,1611,1961,1371,0661,154
    Cash Equivalents-10.8%457512447407513
  Inventory4.3%325311320328317
  Net PPE3.5%311301302309312
  Goodwill6.2%1,0399789901,0091,013
Liabilities0.1%2,0852,0832,0922,0572,098
  Current Liabilities5.4%321304296316340
  Long Term Debt-1.4%810821833--
Shareholder's Equity4.6%1,8041,7241,6611,6151,685
  Retained Earnings6.4%879826776731699
  Additional Paid-In Capital0.7%1,2771,2681,2601,2671,265
Shares Outstanding-0.2%83.0083.0084.00--
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations6.5%264248263288312
  Share Based Compensation-2.5%28.0028.0027.0036.0036.00
Cashflow From Investing-87.5%-58.58-31.24-54.52-57.94-161
Cashflow From Financing-63.9%-251-153-144-228-98.23
  Buy Backs0%1251251251250.00

Risks for IART

What is the probability of a big loss on IART?

63.1%


Probability that Integra LifeSciences Holdings stock will be more than 20% underwater in next one year

48.1%


Probability that Integra LifeSciences Holdings stock will be more than 30% underwater in next one year.

8.5%


Probability that Integra LifeSciences Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IART drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Integra LifeSciences Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for IART

Cumulative Returns on IART

10.9%


10-Year Cumulative Returns

7.2%


7-Year Cumulative Returns

-1.5%


5-Year Cumulative Returns

7.0%


3-Year Cumulative Returns

What are the long-term rolling returns for IART?

FIve years rolling returns for Integra LifeSciences Holdings.

Annualized Returns

Which funds bought or sold IART recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-36.39
-155,884
830,116
-%
2023-03-06
Rockefeller Capital Management L.P.
added
4.09
6,000
21,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-0.39
1,096,780
4,541,780
0.01%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
9.00
1,009
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
9.25
1,905,000
6,173,000
0.06%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
25.00
4,543
14,543
-%
2023-02-21
KB FINANCIAL PARTNERS, LLC
reduced
-2.65
1,000
6,000
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-3.01
21,125,000
95,709,000
0.11%
2023-02-21
MACQUARIE GROUP LTD
added
11.81
1,250,000
6,412,000
0.01%
2023-02-21
NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC
reduced
-35.92
-66,985
377,015
0.01%

1–10 of 40

Latest Funds Activity

Are funds buying IART calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own IART
No. of Funds

Integra LifeSciences Holdings News

Stocks Register

Analyze Alphatec Holdings Inc. (NASDAQ: ATEC) Before Investing..

Stocks Register,
19 hours ago

Schedule 13G FIlings of Integra LifeSciences Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
tru st partnership, l.p.
10.20%
8,515,930
SC 13G/A
Feb 13, 2023
champlain investment partners, llc
6.30%
5,259,524
SC 13G/A
Feb 09, 2023
morgan stanley
6.8%
5,681,483
SC 13G/A
Feb 09, 2023
vanguard group inc
8.56%
7,147,759
SC 13G/A
Feb 06, 2023
wellington management group llp
6.84%
5,709,663
SC 13G/A
Feb 03, 2023
blackrock inc.
8.6%
7,143,236
SC 13G/A
Jul 08, 2022
capital research global investors
4.7%
3,869,770
SC 13G/A
Feb 14, 2022
tru st partnership, l.p.
10.32%
8,740,930
SC 13G/A
Feb 11, 2022
champlain investment partners, llc
6.72%
5,694,837
SC 13G/A
Feb 11, 2022
capital research global investors
9.7%
8,219,133
SC 13G/A

IART Fair Value

Integra LifeSciences Holdings fair value in different scenarios

The table shows the Fair Value estimates for Integra LifeSciences Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

17.17

-67.66%

20.06

-62.22%

32.24

-39.27%

47.72

-10.11%

59.83

12.70%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Integra LifeSciences Holdings Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Integra LifeSciences Holdings

View All Filings
Date Filed Form Type Document
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading

Latest Insider Trading transactions for IART

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
Schwartz Eric
sold (taxes)
-74,183
55.7355
-1,331
evp, chief legal officer & sec
2023-03-13
DAVIS ROBERT T. JR.
sold (taxes)
-77,284
52.61
-1,469
evp & president, tt
2023-03-13
Evoli Lisa
sold (taxes)
-50,453
52.61
-959
evp & chro
2023-03-13
Mosebrook Jeffrey
sold (taxes)
-10,732
52.61
-204
svp, fin, pfo & pao
2023-03-13
McBreen Michael J.
sold (taxes)
-50,137
52.61
-953
evp & president, css
2023-03-12
Evoli Lisa
sold (taxes)
-51,389
52.87
-972
evp & chro
2023-03-12
Schwartz Eric
sold (taxes)
-61,857
52.87
-1,170
evp, chief legal officer & sec
2023-03-12
Mosebrook Jeffrey
sold (taxes)
-15,385
52.87
-291
svp, fin, pfo & pao
2023-03-12
DAVIS ROBERT T. JR.
sold (taxes)
-86,548
52.87
-1,637
evp & president, tt
2023-03-12
McBreen Michael J.
sold (taxes)
-86,125
52.87
-1,629
evp & president, css

1–10 of 50

Jan D. de Witte
3800
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

IART Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Total revenue, net$ 1,557,666$ 1,542,448$ 1,371,868
Costs and expenses:   
Cost of goods sold587,355597,808520,834
Research and development101,19393,05177,381
Selling, general and administrative616,316637,445594,526
Intangible asset amortization13,88216,91427,757
Total costs and expenses1,318,7461,345,2181,220,498
Operating income238,920197,230151,370
Interest income11,9176,7379,297
Interest expense(49,594)(50,395)(71,581)
Gain from sale of businesses64441,7980
Other income, net12,00719,3074,434
Income before income taxes213,894214,67793,520
Provision (benefit) for income taxes33,34445,602(40,372)
Net income$ 180,550$ 169,075$ 133,892
Net income per share   
Basic (in dollars per share)$ 2.18$ 2.00$ 1.58
Diluted (in dollars per share)$ 2.16$ 1.98$ 1.57
Weighted average common shares outstanding (See Note 13):   
Basic (in shares)82,99784,69884,650
Diluted (in shares)83,51685,48585,228

IART Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 456,661$ 513,448
Trade accounts receivable, net of allowances of $4,304 and $4,735263,465231,831
Inventories, net324,583317,386
Prepaid expenses and other current assets116,78991,051
Total current assets1,161,4981,153,716
Property, plant and equipment, net311,302311,703
Right of use asset - operating leases148,28484,543
Intangible assets, net1,126,6091,145,573
Goodwill1,038,8811,013,458
Deferred tax assets, net45,99456,950
Other assets57,19016,440
Total assets3,889,7583,782,383
Current Liabilities:  
Current portion of borrowings under senior credit facility38,12545,000
Current portion of lease liability - operating leases14,62414,775
Accounts payable, trade102,10061,837
Contract liabilities7,2535,295
Accrued compensation78,77192,656
Accrued expenses and other current liabilities80,033120,458
Total current liabilities320,906340,021
Long-term borrowings under senior credit facility733,149824,257
Long-term borrowings under securitization facility104,700112,500
Long-term convertible securities567,341564,426
Lease liability - operating leases157,42090,329
Deferred tax liabilities63,33845,788
Other liabilities138,501120,258
Total liabilities2,085,3552,097,579
Stockholders’ Equity:  
Preferred Stock; no par value; 15,000 authorized shares; none outstanding00
Common stock; $0.01 par value; 240,000 authorized shares; 90,477 and 89,600 issued at December 31, 2022 and 2021, respectively905896
Additional paid-in capital1,276,9771,264,943
Treasury stock, at cost; 6,823 and 4,899 shares at December 31, 2022 and 2021, respectively(362,862)(234,448)
Accumulated other comprehensive income (loss)10,265(45,155)
Retained earnings879,118698,568
Total stockholders’ equity1,804,4031,684,804
Total liabilities and stockholders’ equity$ 3,889,758$ 3,782,383